Postgraduate research opportunities Targeting the Nuclear Import Pathway as a Treatment for Triple Negative Breast Cancer

Apply

Key facts

  • Opens: Wednesday 4 March 2020
  • Number of places: 1
  • Duration: 36 Months

Overview

Cellular Basis of Disease (Health and Wellbeing- Z and N Rattray), Metabolomics (Health and Wellbeing, Measurement and enabling sciences- N Rattray), Drug Delivery (Health and Wellbeing – Z Rattray)
Back to opportunity

Eligibility

We encourage highly-competitive and motivated students with a background in pharmacology, or molecular and cancer biology to apply for this project. A 2:1 degree or higher degree class is a pre-requisite. Experience in cell culture and imaging is desirable.

THE Awards 2019: UK University of the Year Winner
Back to opportunity

Project Details

Breast cancer is the most commonly-diagnosed cancer, and a leading cause of female cancer-associated mortality. Though breast cancer survival has been substantially improved by hormone therapies, patients lacking hormone receptors experience limited therapeutic options and a poor survival outcome. Recent analyses have identified aberrant over-expression of nuclear import machinery (i.e. Karyopherins) as a biomarker of breast cancer aggressiveness. Under homeostatic conditions, the Karyopherin transporter family regulate protein subcellular localization and function which is essential for signal transduction, DNA repair, cellular proliferation and survival. In cancer, aberrant KPNA2 activity leads to pathogenic protein mislocalisation that coupled to tumour mutational burden, gives rise to a highly-invasive tumour phenotype.

This project will consider studying the in vitro effects of Karyopherin depletion on DNA damage repair, cell cycle phase progression, phenotype and survival in a panel of DNA repair proficient and deficient breast cancer cell lines. A combination of metabolomics and quantitative immunofluorescence will be used to track phenotypic changes of baseline and transformed cell models. Triple-negative and aggressive breast cancers are commonly characterized by mutations in DNA repair factors, so in vitro combination effects of Karyopherin depletion and DNA damage repair inhibition on DNA repair and cellular survival will also be investigated. It is anticipated that Karyopherin depletion will lead to loss of cell viability, cellular senescence, and a less-invasive in vitro phenotype.

Knowledge of the association between aberrant Karyopherin over-expression and an aggressive tumour phenotype in parallel to tumour mutational burden offers the scope for discovery of novel drugs, biomarkers and synthetically-lethal synergistic drug combinations.

Techniques used

  • Metabolomics
  • Molecular Biology
  • Data analysis
  • Cell culture
Back to opportunity

Funding details

The University student fees and stipend need to be covered from the student’s own Scholarship.

A bench fee of £12,000 per annum (to be agreed with the funding body) to cover research costs and student conference travels needs to paid as well.

Back to opportunity

Supervisors

Dr Rattray

Dr Zahra Rattray

Senior Lecturer
Strathclyde Institute of Pharmacy and Biomedical Sciences

View profile
Dr Rattray

Dr Nicholas Rattray

Senior Lecturer
Strathclyde Institute of Pharmacy and Biomedical Sciences

View profile
Back to course

Apply

Please apply via the PhD Pharmacy & Biomedical Sciences course page.

 

Number of places: 1

To read how we process personal data, applicants can review our 'Privacy Notice for Student Applicants and Potential Applicants' on our Privacy notices' web page.

Back to course

Contact us

Primary Supervisor: Dr Zahra Rattray Zahra.rattray@strath.ac.uk